[go: up one dir, main page]

CL2009000551A1 - Use of 2- [4- (7-ethyl-5h-pyrrolo [2,3-b] pyrazin-6-yl) -phenyl] -propan-2-ol, or a pharmaceutically acceptable salt thereof, to treat a disorder related to the eyes such as macular degeneration, diabetic retinopathy or diabetic macular edema and pharmaceutical composition comprising said compound. - Google Patents

Use of 2- [4- (7-ethyl-5h-pyrrolo [2,3-b] pyrazin-6-yl) -phenyl] -propan-2-ol, or a pharmaceutically acceptable salt thereof, to treat a disorder related to the eyes such as macular degeneration, diabetic retinopathy or diabetic macular edema and pharmaceutical composition comprising said compound.

Info

Publication number
CL2009000551A1
CL2009000551A1 CL2009000551A CL2009000551A CL2009000551A1 CL 2009000551 A1 CL2009000551 A1 CL 2009000551A1 CL 2009000551 A CL2009000551 A CL 2009000551A CL 2009000551 A CL2009000551 A CL 2009000551A CL 2009000551 A1 CL2009000551 A1 CL 2009000551A1
Authority
CL
Chile
Prior art keywords
diabetic
pyrazin
pyrrolo
propan
eyes
Prior art date
Application number
CL2009000551A
Other languages
Spanish (es)
Inventor
Thomas Oligino
Chang Hahn
Timothy Gillespy
Ramalinga Dharanipragada
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2009000551A1 publication Critical patent/CL2009000551A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Uso de 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol, o una sal farmacéuticamente aceptable del mismo, para tratar un trastorno relacionado con los ojos como la degeneración macular, retinopatía diabética o edema macular diabético y composición farmacéutica que comprende a dicho compuesto.Use of 2- [4- (7-ethyl-5h-pyrrolo [2,3-b] pyrazin-6-yl) -phenyl] -propan-2-ol, or a pharmaceutically acceptable salt thereof, to treat a disorder related to the eyes such as macular degeneration, diabetic retinopathy or diabetic macular edema and pharmaceutical composition comprising said compound.

CL2009000551A 2008-03-10 2009-03-09 Use of 2- [4- (7-ethyl-5h-pyrrolo [2,3-b] pyrazin-6-yl) -phenyl] -propan-2-ol, or a pharmaceutically acceptable salt thereof, to treat a disorder related to the eyes such as macular degeneration, diabetic retinopathy or diabetic macular edema and pharmaceutical composition comprising said compound. CL2009000551A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3507308P 2008-03-10 2008-03-10

Publications (1)

Publication Number Publication Date
CL2009000551A1 true CL2009000551A1 (en) 2009-08-21

Family

ID=40583469

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000551A CL2009000551A1 (en) 2008-03-10 2009-03-09 Use of 2- [4- (7-ethyl-5h-pyrrolo [2,3-b] pyrazin-6-yl) -phenyl] -propan-2-ol, or a pharmaceutically acceptable salt thereof, to treat a disorder related to the eyes such as macular degeneration, diabetic retinopathy or diabetic macular edema and pharmaceutical composition comprising said compound.

Country Status (22)

Country Link
EP (1) EP2285378A1 (en)
JP (1) JP2011513488A (en)
KR (1) KR20110009084A (en)
CN (1) CN101965188A (en)
AR (1) AR070975A1 (en)
AU (1) AU2009223501A1 (en)
BR (1) BRPI0909659A2 (en)
CA (1) CA2717991A1 (en)
CL (1) CL2009000551A1 (en)
CO (1) CO6290691A2 (en)
CR (1) CR11644A (en)
DO (1) DOP2010000266A (en)
IL (1) IL207906A0 (en)
MA (1) MA32211B1 (en)
MX (1) MX2010008308A (en)
NI (1) NI201000131A (en)
NZ (1) NZ587906A (en)
RU (1) RU2010141560A (en)
SV (1) SV2010003658A (en)
TW (1) TW200950784A (en)
WO (1) WO2009114373A1 (en)
ZA (1) ZA201005337B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074776A1 (en) 2008-12-18 2011-02-09 Sanofi Aventis METHOD TO TREAT MACULAR DEGENERATION; MODULATING THE PATIENT'S IMMUNE SYSTEM
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1050191B (en) * 1999-12-24 2011-04-29 Aventis Pharma Limited Azaindoles
CA2400923A1 (en) * 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
NZ567241A (en) * 2005-09-30 2010-08-27 Miikana Therapeutics Inc Substituted pyrazole compounds
CL2007002617A1 (en) * 2006-09-11 2008-05-16 Sanofi Aventis COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRAZIN-6-ILO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT INFLAMMATION OF THE ARTICULATIONS, Rheumatoid Arthritis, TUMORS, LYMPHOMA OF THE CELLS OF THE MANTO.

Also Published As

Publication number Publication date
AR070975A1 (en) 2010-05-19
CR11644A (en) 2010-11-22
NI201000131A (en) 2011-09-29
KR20110009084A (en) 2011-01-27
TW200950784A (en) 2009-12-16
EP2285378A1 (en) 2011-02-23
WO2009114373A1 (en) 2009-09-17
MA32211B1 (en) 2011-04-01
SV2010003658A (en) 2011-01-31
NZ587906A (en) 2011-12-22
DOP2010000266A (en) 2010-09-30
JP2011513488A (en) 2011-04-28
ZA201005337B (en) 2011-04-28
RU2010141560A (en) 2012-04-20
CO6290691A2 (en) 2011-06-20
CN101965188A (en) 2011-02-02
AU2009223501A1 (en) 2009-09-17
BRPI0909659A2 (en) 2015-09-22
IL207906A0 (en) 2010-12-30
CA2717991A1 (en) 2009-09-17
MX2010008308A (en) 2010-08-11

Similar Documents

Publication Publication Date Title
ECSP12011799A (en) ESPIROPIPERIDINE AND PHARMACEUTICAL USE OF THE SAME COMPOUNDS
CO7101245A2 (en) Substituted benzaldehyde compounds and methods for use in increasing tissue oxygenation
AR084691A1 (en) TOPICAL USE FORMULATION FOR A JAK INHIBITOR AND METHOD TO TREAT SKIN DISORDER
UY35781A (en) KRAS G12C INHIBITORS.
CL2011000973A1 (en) Compounds derived from pyrazolo [1,5-a] pyrimidine3-cabroxamide; pharmaceutical composition that includes them, and use to treat or reduce the severity of a disease or condition that responds to the inhibition of the activity of a jak kinase.
GT201200164A (en) "NEW SPYROPIPERIDINE COMPOUNDS"
CL2011000170A1 (en) Solid and stabilized pharmaceutical composition comprising a pharmaceutically active ingredient, titanium oxide and a plasticizer; procedure to stabilize the pharmaceutical composition during a light irradiation.
UY35040A (en) PIRROLOPIRIMIDINILAMINO-BENZOTIAZOLONAS REPLACED
NI201600049A (en) KRAS G12C INHIBITORS
ECSP13012611A (en) PIRAZOL-AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2
SV2015005115A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
DOP2010000304A (en) COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME
GT201400009A (en) 4-IMIDAZOPIRIDAZIN-1-IL-BENZAMIDAS AND 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDAS AS BTK INHIBITORS
PE20141406A1 (en) 4- (8-METHOXY-1 - ((1-METOXYPROPAN-2-IL) -2- (TETRAHYDRO-2H-PYRAN-4-IL) -1H-IMIDAZO [4,5-C] QUINOLIN-7-IL) -3,5-DIMETHYLISOXAZOLE AND ITS USE AS A BROMODOMINIUM INHIBITOR
ECSP077349A (en) NEW DERIVATIVES OF SULFONAMIDE AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
UY32461A (en) 6-METHYL-5- (METHYL-1H-PIRAZOL-5-IL) -N - {[E- (METILSULFONIL) PIRIDIN-2-IL] METHYL -2-OXO-1- [3- (TRIFLUOROMETIL ) PHENYL] -1,2-DIHIDROPIRIDIN-3-CARBOXAMIDA
CL2013000481A1 (en) Method and to improve the efficacy and / or reduce the side effects of a suboptimally administered pharmacotherapy comprising the administration of a substituted hexitol; pharmaceutical composition; pharmaceutical combination; Use to treat proliferative diseases.
CL2015003072A1 (en) Long-term colchicine release formulations and methods of use thereof.
CR20150114A (en) COVERED PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
UY33277A (en) SPIRO-TETRACICLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE
AR085616A1 (en) INHALABLE PHARMACEUTICAL COMPOSITION UNDERSTANDING GLICOPIRROLATE, USE
ECSP077323A (en) NEW DERIVATIVES OF SULFONAMIDE AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
CL2009001077A1 (en) Polymeric particulate carrier comprising a biological agent in aqueous phase in a hollow lumen; procedure to deliver a protein to the eye; pharmaceutical composition comprising said vehicle; and its use for prophylaxis and treating diseases or disorders of the eye.
CL2013000736A1 (en) Use of ester prodrugs of [3- (1- (1h-imidazol-4-yl) ethyl) -2-methyl-phenyl] methanol to prepare a medicament useful in the treatment of retinal diseases such as wet and dry macular degeneration , and diabetic retinopathy; and use of the composition comprising said compounds.
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION